{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:38:32Z","timestamp":1789688312545,"version":"4.0.1"},"reference-count":54,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Global Initiative for Asthma Italy\/Federasma\/Italian Society of Allergy, Asthma"},{"name":"AstraZeneca, GlaxoSmithKline, Novartis, and Sanofi"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background\/Objectives: Severe allergic asthma is usually treated with omalizumab; however, this drug may not be effective for every patient. By its action, dupilumab could be an alternative in these patients. The objective of this study was to evaluate the efficacy of dupilumab in patients with severe allergic asthma, non-responsive to omalizumab, according to the maintenance of their oral corticosteroid (OCS) dose, an exacerbation rate decrease, or poor control of the disease, despite optimized treatment. Methods: A retrospective analysis of data from severe asthma clinics was performed, observing the efficacy of the switch to dupilumab in patients who experienced a failed treatment with omalizumab. Results: Forty-two patients were included. Dupilumab proved to be effective in patients who experienced a failed omalizumab treatment, with a significant reduction in the exacerbation number and OCS use. Furthermore, remission of the disease, according to the Severe Asthma Network of Italy (SANI) criteria, was achieved in 35 patients, with complete remission in 19 (45%) and partial remission in 16 (38%). The analysis of the predictors of the success of dupilumab therapy in achieving clinical remission, through univariate analysis of the data at baseline, showed that complete remission was more easily reached in patients with concomitant aspirin (ASA) intolerance or in those with nasal polyposis. Conclusions: Dupilumab is an effective drug for the treatment of patients with severe asthma with an allergic component, with better benefits in patients with an ASA intolerance or nasal polyposis.<\/jats:p>","DOI":"10.3390\/jpm15020043","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T05:49:54Z","timestamp":1737611394000},"page":"43","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dupilumab Effectiveness in Patients with Severe Allergic Asthma Non-Responsive to Omalizumab"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3661-5731","authenticated-orcid":false,"given":"Diego","family":"Bagnasco","sequence":"first","affiliation":[{"name":"Respiratory and Allergy Clinic, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"},{"name":"Department of Internal Medicine (DIMI), University of Genoa, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Bondi","sequence":"additional","affiliation":[{"name":"Respiratory and Allergy Clinic, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"},{"name":"Department of Internal Medicine (DIMI), University of Genoa, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7249-7616","authenticated-orcid":false,"given":"Luisa","family":"Brussino","sequence":"additional","affiliation":[{"name":"SCDU Immunology and Allergology, AO Ordine Mauriziano, 10128 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9955-194X","authenticated-orcid":false,"given":"Stefania","family":"Nicola","sequence":"additional","affiliation":[{"name":"SCDU Immunology and Allergology, AO Ordine Mauriziano, 10128 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8639-2882","authenticated-orcid":false,"given":"Paolo","family":"Cameli","sequence":"additional","affiliation":[{"name":"Respiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Tiotiu","sequence":"additional","affiliation":[{"name":"Department of Pneumology, University Hospital Saint-Luc, 1200 Brussels, Belgium"},{"name":"Pole Pneumology, ENT, and Dermatology-LUNS, Institute of Experimental and Clinical Research (IREC), UCLouvain, 1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3876-8587","authenticated-orcid":false,"given":"Giuseppe","family":"Guida","sequence":"additional","affiliation":[{"name":"Severe Asthma and Rare Lung Disease Unit, San Luigi Gonzaga University Hospital, Orbassano, 10043 Turin, Italy"},{"name":"Department of Clinical and Biological Sciences, University of Turin, Orbassano, 10043 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Gollinucci","sequence":"additional","affiliation":[{"name":"Severe Asthma and Rare Lung Disease Unit, San Luigi Gonzaga University Hospital, Orbassano, 10043 Turin, Italy"},{"name":"Department of Clinical and Biological Sciences, University of Turin, Orbassano, 10043 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2298-1623","authenticated-orcid":false,"given":"Dina","family":"Visca","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, 21049 Tradate, Italy"},{"name":"Department of Medicine and Surgery, Respiratory Diseases, University of Insubria, 21100 Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Spanevello","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, 21049 Tradate, Italy"},{"name":"Department of Medicine and Surgery, Respiratory Diseases, University of Insubria, 21100 Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6563-4942","authenticated-orcid":false,"given":"Laura","family":"Pini","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Unit, ASST-Spedali Civili, 25123 Brescia, Italy"},{"name":"Department of Clinical and Experimental Sciences, University of Brescia, 25122 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7383-1487","authenticated-orcid":false,"given":"Marco","family":"Caminati","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Verona, 37129 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4172-3216","authenticated-orcid":false,"given":"Gianenrico","family":"Senna","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Verona, 37129 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Caruso","sequence":"additional","affiliation":[{"name":"UOSD Allergology and Clinical Immunology Unit, Fondazione Policlinico Universitario \u201cA. Gemelli\u201d IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1821-7262","authenticated-orcid":false,"given":"Rikki Frank","family":"Canevari","sequence":"additional","affiliation":[{"name":"ENT Department, IRCCS Policlinico San Martino, University of Genoa, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7489-1105","authenticated-orcid":false,"given":"Melania","family":"Bertolini","sequence":"additional","affiliation":[{"name":"ENT Department, IRCCS Policlinico San Martino, University of Genoa, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Fedele","sequence":"additional","affiliation":[{"name":"Respiratory and Allergy Clinic, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"},{"name":"Department of Internal Medicine (DIMI), University of Genoa, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Mincarini","sequence":"additional","affiliation":[{"name":"Respiratory and Allergy Clinic, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"},{"name":"Department of Internal Medicine (DIMI), University of Genoa, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"},{"name":"Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, 20089 Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Braido","sequence":"additional","affiliation":[{"name":"Respiratory and Allergy Clinic, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"},{"name":"Department of Internal Medicine (DIMI), University of Genoa, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the SANI group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(17)30879-6","article-title":"After Asthma: Redefining Airways Diseases","volume":"391","author":"Pavord","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bush, A. (2019). Pathophysiological Mechanisms of Asthma. Front. Pediatr., 7.","DOI":"10.3389\/fped.2019.00068"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2147\/JAA.S402326","article-title":"Asthma Prevalence and Phenotyping in the General Population: The LEAD (Lung, hEart, sociAl, boDy) Study","volume":"16","author":"Schiffers","year":"2023","journal-title":"J. Asthma Allergy"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/all.15076","article-title":"Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications","volume":"77","author":"Agusti","year":"2021","journal-title":"Allergy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/87551225221116266","article-title":"Complications of Corticosteroid Therapy: A Comprehensive Literature Review","volume":"38","author":"Koshi","year":"2022","journal-title":"J. Pharm. Technol."},{"key":"ref_6","unstructured":"Yasir, M., Goyal, A., and Sonthalia, S. (2023). Corticosteroid Adverse Effects, StatPearls."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2165\/00063030-200216050-00009","article-title":"Omalizumab: Anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25","volume":"16","author":"Bayes","year":"2002","journal-title":"BioDrugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaci.2012.01.033","article-title":"Omalizumab and the risk of malignancy: Results from a pooled analysis","volume":"129","author":"Busse","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bhutani, M., Yang, W.H., H\u00e9bert, J., de Takacsy, F., and Stril, J.-L. (2017). The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183869"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17520","article-title":"Omalizumab for the treatment of severe persistent allergic asthma: A systematic review and economic evaluation","volume":"17","author":"Norman","year":"2013","journal-title":"Health Technol. Assess."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2103130","DOI":"10.1183\/13993003.03130-2021","article-title":"Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients","volume":"60","author":"Humbert","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/1744666X.2020.1856658","article-title":"\u2018Real-world\u2019 effectiveness of omalizumab in adults with severe allergic asthma: A meta-analysis","volume":"17","author":"Faulkner","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100721","DOI":"10.1016\/j.waojou.2022.100721","article-title":"Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps","volume":"15","author":"Bagnasco","year":"2022","journal-title":"World Allergy Organ. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1185\/030079907X226258","article-title":"Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: A pooled analysis","volume":"23","author":"Busse","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1111\/all.15008","article-title":"Potential cancer risk with omalizumab? A disproportionality analysis of the WHO\u2019s VigiBase pharmacovigilance database","volume":"76","author":"Mota","year":"2021","journal-title":"Allergy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/all.15591","article-title":"Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients","volume":"78","author":"Spekhorst","year":"2022","journal-title":"Allergy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/JAA.S385645","article-title":"Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization","volume":"16","author":"Corren","year":"2023","journal-title":"J. Asthma Allergy"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.alit.2020.01.002","article-title":"Dupilumab: Basic aspects and applications to allergic diseases","volume":"69","author":"Matsunaga","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"109130","DOI":"10.1016\/j.clim.2022.109130","article-title":"IL-4 receptor blockade is a global repressor of na\u00efve B cell development and responses in a dupilumab-treated patient","volume":"244","author":"Mountz","year":"2022","journal-title":"Clin. Immunol."},{"key":"ref_21","first-page":"2486","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"J. Med."},{"key":"ref_22","first-page":"2475","article-title":"Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaip.2019.08.050","article-title":"Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma","volume":"8","author":"Corren","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1080\/02770903.2024.2376919","article-title":"SANI clinical remission definition: A useful tool in severe asthma management","volume":"61","author":"Canonica","year":"2024","journal-title":"J. Asthma"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence from PROSPERO, A Prospective Real-World Study","volume":"7","author":"Casale","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000487482","article-title":"\u201cReal-life\u201d Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma","volume":"27","author":"Arifhodzic","year":"2018","journal-title":"Med. Princ. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e2023S123","DOI":"10.1590\/1806-9282.2023s123","article-title":"Asthma and pregnancy","volume":"69","author":"Caetano","year":"2023","journal-title":"Rev. Assoc. Med. Bras."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1016\/j.jaip.2022.08.013","article-title":"Safety of Biologics for Atopic Diseases During Pregnancy","volume":"10","author":"Shakuntulla","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.iac.2022.07.001","article-title":"Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Dermatitis During Pregnancy and Lactation","volume":"43","author":"Ramos","year":"2022","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18176\/jiaci.0391","article-title":"Effectiveness of Omalizumab in Severe Allergic Asthma and Nasal Polyposis: A Real-Life Study","volume":"30","author":"Tiotiu","year":"2020","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e047344","DOI":"10.1136\/bmjopen-2020-047344","article-title":"Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: A systematic review and meta-analysis of randomised controlled trials","volume":"11","author":"Wu","year":"2021","journal-title":"BMJ Open"},{"key":"ref_35","first-page":"110","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2012","journal-title":"Clin. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100670","DOI":"10.1016\/j.waojou.2022.100670","article-title":"Omalizumab is effective in nasal polyposis with or without asthma, a real-life study","volume":"15","author":"Tat","year":"2022","journal-title":"World Allergy Organ. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0091-6749(97)70276-8","article-title":"The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4 or CD8 T cells","volume":"100","author":"Punnonen","year":"1997","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/380627a0","article-title":"Essential role of Stat6 in IL-4 signalling","volume":"380","author":"Takeda","year":"1996","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1016\/j.jaip.2021.02.059","article-title":"Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry (ISAR)","volume":"9","author":"Denton","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1016\/j.jaip.2022.06.036","article-title":"Dupilumab Is Effective in Patients with Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype","volume":"10","author":"Rabe","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Bagnasco, D., De Ferrari, L., Bondi, B., Candeliere, M.G., Mincarini, M., Riccio, A.M., and Braido, F. (2024). Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115972"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thoraxjnl-2021-217325","article-title":"Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide","volume":"77","author":"Couillard","year":"2021","journal-title":"Thorax"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3399\/bjgp23X735813","article-title":"Fractional exhaled nitric oxide (FeNO): The future of asthma care?","volume":"73","author":"Wang","year":"2023","journal-title":"Br. J. Gen. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2021.04.065","article-title":"Total IgE variability is associated with future asthma exacerbations: A one-year prospective cohort study","volume":"9","author":"Yuan","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/coa.13177","article-title":"Minimal clinically important difference for the 22-item Sinonasal Outcome Test in medically managed patients with chronic rhinosinusitis","volume":"43","author":"Phillips","year":"2018","journal-title":"Clin. Otolaryngol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jaci.2023.03.014","article-title":"Omalizumab ameliorates extrarespiratory symptoms in patients with aspirin-exacerbated respiratory disease","volume":"151","author":"Hayashi","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2102583","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: What is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pharmthera.2011.01.002","article-title":"Remission of asthma: The next therapeutic frontier?","volume":"130","author":"Upham","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2023","journal-title":"Allergy"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MCP.0000000000001068","article-title":"Remission in asthma","volume":"30","author":"Lommatzsch","year":"2024","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(23)00415-0","article-title":"Pioneering a paradigm shift in asthma management: Remission as a treatment goal","volume":"12","author":"Lommatzsch","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Bagnasco, D., Nicola, S., Testino, E., Brussino, L., Pini, L., Caminati, M., Piccardo, F., Canevari, R.F., Melissari, L., and Ioppi, A. (2023). Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders. Biomedicines, 11.","DOI":"10.3390\/biomedicines11092424"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Bagnasco, D., Bondi, B., Caminati, M., Nicola, S., Pini, L., Milanese, M., Brussino, L., Senna, G., Canonica, G.W., and Braido, F. (2024). Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab. Biomedicines, 12.","DOI":"10.3390\/biomedicines12050960"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/2\/43\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:34:17Z","timestamp":1759919657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/2\/43"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jpm15020043"],"URL":"https:\/\/doi.org\/10.3390\/jpm15020043","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}